ZYDUS CADILA GETS USFDA APPROVAL TO MARKET DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECTION

Highlights

• Zydus Cadila in the statement issued on Friday said that it has received final approval from the USFDA to market Doxorubicin Hydrochloride Liposome injection in the strengths of 20 mg/10 mL (2mg/mL) and 50 mg/25 mL (2mg/mL) single-dose vials

• Zydus Casu...